← brief for 2026-09-16 · Slowing decline

Sequential liraglutide and setmelanotide therapy in Bardet-Biedl Syndrome: metabolic and renal outcomes in a real-world case report and literature review.

Article C Peer reviewed Observational

Key takeaways

This report follows one adult with Bardet-Biedl syndrome, a rare genetic condition that causes obesity and kidney disease. The person took liraglutide, a GLP-1 weight-loss drug, and later setmelanotide, a drug that works on hunger signals in the brain. The authors say weight, blood sugar and kidney health all improved, and they review earlier published cases too. This is a single case, so it shows a link, not proof that the drugs caused the change.

Who did this work

Pasquariello T · Secondulfo F · Roscini AR · Nardi E · Prosperi E · Capasso G · Perna AF · Zacchia M

Source

Article · PubMed, the drug frontier · 2026 Sep 15
https://pubmed.ncbi.nlm.nih.gov/42743093/